Lifecore Biomedical Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Lifecore Biomedical Inc in the first quarter 2026?
Due to the lack of equity, it was not possible to calculate Lifecore Biomedical Inc 's return on equity (ROE) in its first quarter 2026

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Mar 31 2026) I. Quarter	(Sep 30 2025) I. Quarter	(May 25 2025) IV. Quarter	(Feb 23 2025) III. Quarter	(Nov 24 2024) II. Quarter
Y / Y Equity Change	-	-	-88.19 %	-87.4 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-46	-39	-44	-49	-16
Return On Equity (TTM)	-	-3573.75 %	-1614.59 %	-941.66 %	-180.15 %
LFCR's Total Ranking	#	#	#	#	#
Equity (TTM) in Millions	-28	-11	1	2	11
Seq. Equity Change	-	-	-40.06 %	-80.3 %	-
Seq. Net Income Change	-	-	-	-	-

Back to LFCR Management Effectiveness >> LFCR's 5 Years Annual ROE >> Compare LFCR ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	#
Sector	#
Overall	#

Return On Equity Statistics
High	Average	Low
0 %	0 %	0 %

News about Lifecore Biomedical Inc Return on Equity ROE

Lifecore Biomedical Strengthens Operations and Financial Health with Key Appointment and $24.3 Million Capital Raise,

Lifecore Biomedical Enhances Its Operational Foundation with Strategic Leadership Appointment and Capital InfusionIn a series of strategic maneuvers aimed at bolstering its operational capabilities and financial standing, Lifecore Biomedical Inc. has taken significant steps to navigate a challenging landscape within the life sciences sector. Recently, the company appointed Thomas Guldager as its new Vice President of Operations, coupled with a successful Private Investment in Public Equity (PIPE) transaction that raised $24.3 million. These developments illustrate Lifecore’s commitment to not only weathering current financial challenges but also positioning itself for future growth. Leadership Enhancements Amidst Financial AdversityThe appointment of Thomas Guldager comes at a pivotal moment for Lifecore Biomedical. Guldager brings with him a robust background in pharmaceutical manufacturing operations and finance, traits that are expected to significantly contribute to the company’s performance and productivity. His extensive experience is poised to enhance operational efficiencies and drive cost-effectiveness at a time when the company is aggressively seeking to streamline its processes.

Navigating Legal Challenges and Achieving Record ROE: Lifecore Biomedical Strives for Success amidst Shareholder Turbulence,

Title for the Objective of the Navigating Legal Challenges: Lifecore Biomedical Faces Shareholder Turbulence and High ROE in Q4 2024

In a recent development, Lifecore Biomedical Inc announced the appointment of Brikkelle Thompson as the Senior Vice President of Human Resources. With nearly 25 years of experience driving top-performing cultures and building exceptional teams, Thompson s addition to the leadership team is expected to further enhance the company s human resource strategies and contribute to its continued success.
Meanwhile, Lifecore Biomedical Inc achieved a remarkable return on equity (ROE) of 284.97% in the fourth quarter of 2024, reaching a new high for the company. This exceptional performance demonstrates the company s ability to generate substantial returns for its shareholders and establishes their strong market position.

Lifecore Biomedical's Tactical Amendments with Lenders Secure $8 Million Non-Dilutive Liquidity, Drives Growth and Innovation

Lifecore Biomedical Secures $8 Million in Non-Dilutive, Incremental Liquidity through Lender Amendments
In a recent move, Lifecore Biomedical, a leading medical device company, has successfully executed a series of incremental liquidity initiatives, resulting in approximately $8 million of much-needed funding. These initiatives, accomplished through various amendments with lenders, provide the company with essential non-dilutive capital to fuel its growth and innovation efforts.
The financing landscape for biomedical companies can be particularly challenging, with traditional sources of funding often falling short in meeting the unique demands of the industry. Lifecore Biomedical, mindful of these challenges, has proactively pursued alternative means to ensure its financial stability.

Lifecore Biomedical Faces Financial Challenges but Demonstrates Resilience in the Pharmaceutical Industry

Lifecore Biomedical, Inc. (NASDAQ: LFCR), a leading contract development and manufacturing organization (CDMO) in the pharmaceutical industry, recently provided a business update that indicates turbulent times for the company. Their shares experienced a significant decline of -8.41%, while a cumulative net loss of -$65 million was recorded during the 12-month period ending in the third quarter of 2023. As a result, Lifecore Biomedical reported a negative return on equity (ROE) of -87.45%.
These figures raise concerns as investors evaluate the performance of the Chaska-based biotech company. The unexpected downturn in stock value and substantial financial losses, though alarming, should be considered in the broader context of the industry landscape. Despite these setbacks, Lifecore Biomedical managed to achieve the highest return on equity among companies in the Major Pharmaceutical Preparations sector.

LFCR Annual Return On Equity	(May 25 2025) 2025	(May 26 2024) 2024	(May 28 2023) 2023	(May 29 2022) 2022
Total Equity in Millions	1	11	-4	91	203
Y / Y Equity Change	-88.19 %	-	-	-55.27 %	-12.23 %
Net Income in Millions	-44	12	-100	-115	0
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-3305.91 %	106.17 %	-	-126.44 %	-

Back to LFCR Management Effectiveness >> LFCR's 5 Years Annual ROE >> Compare LFCR ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
LFCR's' Return on Equity at Yahoo Finance
LFCR's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for LFCR's Competitors
Subscribers only: Roe for Lifecore Biomedical Inc 's Suppliers
Subscribers only: Return On Equity for LFCR's Customers

Companies with similar Return On Equity at Mar 31 2026, within Healthcare Sector	ROE
Xeris Biopharma Holdings Inc	791.74 %
Glucotrack Inc	581.98 %
Silexion Therapeutics Corp	516.87 %
Aveanna Healthcare Holdings Inc	242.29 %
Q32 Bio Inc	230.68 %
Emmis Acquisition Corp	224.85 %
Interpace Biosciences Inc	215.31 %
Coherus Oncology inc	214.57 %
Oncotelic Therapeutics Inc	183.27 %
Arbutus Biopharma Corp	169.38 %
Rigel Pharmaceuticals Inc	147.03 %
Fortress Biotech Inc	140.48 %
Halozyme Therapeutics Inc	126.27 %
Petros Pharmaceuticals inc	124.23 %
Advanced Biomed Inc.	121.71 %
Medpace Holdings Inc	120.89 %
Capforce Inc	110.42 %

Date modified: 2026-09-12T06:10:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.